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Introduction
Solitary pulmonary nodules (SPNs), defined as spherical 
lesions that measure up to 3 cm in diameter and that are 
completely surrounded by pulmonary parenchyma(1,2), 
are quite commonly seen in clinical practice. Generally, 
SPNs are discovered incidentally through chest X-rays
or computerized tomography (CT) scans that are 
performed for unrelated purposes(3). It is projected
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that around half  of  heavy smokers over the age of  50 
may have SPNs. The incidence of  cancer in patients 
with SPNs ranges from 10 to 70 percent(4). The early 
differentiation of  malignant from benign SPNs is very 
critical because it represents a totally different way 
of  management and prognosis(1,3). Benign SPNs 
are most commonly caused by chronic smoking, 
infections, intrapulmonary lymph node, and vascular 
abnormalities(5). In most cases, benign SPNs require 
no treatment. Malignant SPNs, however, generally 
represent an early stage of  lung cancer or metastatic 
cancers that have spread to the lung from other 
regions of  the body(6). It is known that lung cancer 
is the most common cause of  cancer-related deaths 
around the world, accounting for more deaths annually 
than liver, colon, breast, and prostate cancers(7). The 
survival rates of  lung cancer remain frustratingly low, 
with a 15% of  5-year survival rate, whereas the early 
diagnosis and proper management of  lung cancer 
may lead to an increase in 5-year survival rates up to 
70-80%(7,8). Therefore, it is critical to improve the 
early differentiation of  malignant from benign SPNs 
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Abstract
Background: An early differentiation of  malignant from benign solitary pulmonary nodules (SPNs) is essential for 
management and prognosis of  lung cancer. 
Objectives: Here we investigated whether measurement of  circulating sex hormones could be useful for an early detection 
of  malignancy among patients with SPNs. 
Methods: We recruited 47 patients with malignant SPNs, 45 patients with benign SPNs, and 32 healthy persons. Testosterone, 
estradiol, and progesterone were measured. Carcinoembryonic antigen (CEA) as well as TNF-α, IL-1 and IL-6 were also 
measured. 
Results: We found that sex hormones were decreased significantly in patients with malignant SPNs, as compared to patients 
with benign SPNs and healthy controls (P<0.05). Sex hormones levels showed a trend to decline in patients with benign 
SPNs as compared to normal controls, but the difference was not statistically significant (P>0.05). CEA levels were only 
abnormally elevated in eight patients with lung adenocarcinoma. The inflammatory cytokines were remarkably higher in 
both patients than in normal controls. However, there was no statistical difference in these cytokines among patients. 
Conclusions: The reduced sex hormones levels seemed to be uniquely associated with lung cancer. Therefore, measurement 
of  sex hormones may have clinical potential in the diagnosis of  malignancy in patients with SPNs. 
Keywords: solitary pulmonary nodules (SPNs), sex hormones, lung cancer, biomarkers 
African Health Sciences 2014; 14(2):356-363
DOI: http://dx.doi.org/10.4314/ahs.v14i2.10
African Health sciences Vol 14 No. 2 June 2014                  356
in patients. Nevertheless, the asymptomatic nature 
of  SPNs makes for a significant clinical challenge in 
diagnosing and differentiating between malignant and 
benign SPNs(9,10). 
For accurate diagnosis of  SPNs, it usually includes 
observation with serial chest X-rays, CT scan, 
transthoracic needle biopsy, and surgical resection(1). 
So far, chest X-ray is conducted to identify SPNs as 
a routine screening test, which avoids unnecessary 
surgery in case of  benign disease but delays appropriate 
diagnosis and management, when malignancy really 
exists. Furthermore, serial chest X-rays may lead to 
unnecessary radiation exposure, anxiety, cost, and 
low accuracy. CT or positron emission tomography 
(PET) scan is more sensitive and more specific than 
chest X-ray, and is used to do further imaging when 
some SPNs are seen on chest X-ray(1,11). However, 
the widespread use and improved sensitivity of  CT or 
PET dramatically increase the number of  SPNs seen 
in asymptomatic individuals. Only a small fraction 
of  SPNs turns out to be lung tumors. So it is not 
recommended to apply CT or PET scans in every such 
case. Biopsy of  the nodules via transthoracic needle or 
surgical resection is the “gold standard” diagnostic test 
and can confirm if  SPNs are cancerous or not, but this 
approach is invasive, potentially risky(2,4). Specifically, 
surgery should be avoided in case of  benign SPNs 
growths. Overall, it is clinically important to develop 
some new diagnostic strategies with high accuracy that 
are able to detect lung cancer in patients with SPNs in a 
minimally invasive manner. 
Over years, a number of  lung cancer-related markers 
have been identified, but few have turned out to be 
clinically relevant for the early diagnosis of  lung cancer. 
It has been reported that sex hormones influence 
almost every aspect of  human physiological functions, 
activities, and behaviors(12). Sex hormones are 
thought to have a role in the etiology of  some cancers; 
disturbance in sex hormones is an important feature 
of  cancer pathophysiology(13). However, most studies 
have been done on sex hormone-sensitive cancers in 
reproductive organs such as breast, prostate, cervix 
and ovary. It has been increasingly recognized that sex 
hormones also have a significant influence on cancers 
in non-reproductive organs or tissues such as colon, 
lung and esophagus(13,14). The altered circulating 
sex hormones have been observed in human lung 
carcinoma, suggesting that sex hormones contribute to 
the development and progression of  lung tumor(12). 
But the available reports were seemingly conflicting 
and complex. The role of  sex hormones involving lung 
cancer is yet to be elucidated.
The objective of  this study was to measure circulating 
sex hormones in male patients with SPNs, with 
exploration of  whether circulating sex hormones have 
the potential to function as biomarkers in identification 
of  lung cancer among patients with SPNs. 
Methods 
Patients and clinical samples
A total of  45 male patients with benign SPNs (age 
range between 38-72) and 47 male patients with 
malignant SPNs (age range between 40-79) as well as 32 
male healthy controls (age range between 39-69) were 
included in this study. 
All patients didn’t receive radiation, chemotherapy, or 
other medical treatment and gave their blood samples 
preoperatively. Controls were healthy volunteers with no 
obvious illness who agreed to provide blood samples, 
health information and written informed consent. 
Serum was separated from the blood samples, aliquoted 
and stored at -80°C for future analysis. For histological 
analysis, lung tissue specimens were resected surgically 
and fixed in 10% neutral formalin, embedded in paraffin, 
cut into 5 μm sections, and stained with hematoxylin & 
eosin.
All subjects gave their informed consent for 
inclusion before they participated in the study. The 
study was approved by appropriate ethics committees 
and institutional review boards, which followed the 
recommendations of  the Declaration of  Helsinki for 
biomedical research involving human subjects.
Measurement of  circulating sex hormones and 
CEA
Serum levels of  testosterone, estradiol, and progesterone 
that represent both male and female sex hormones 
were measured by using commercially available 
enzyme-linked immunosorbent assay (ELISA) kits 
(Phoenix Pharmaceuticals, INC, USA), according to 
manufacturer’s instructions. Serum levels of  CEA were 
also measured by ELISA kit (Phoenix Pharmaceuticals, 
INC, USA). The detection limits for testosterone, 
estradiol, and progesterone as well as CEA are 0.05 ng/
ml, 10 pg/ml, 0.06 ng/ml, and 1.0 ng/ml, respectively. 
Determination of  serum TNF-α, IL-β 1and IL-6 
levels 
Serum samples were analyzed for TNF-α, IL-1β and 
IL-6 levels using ELISA kits (R&D Systems Inc, USA), 
according to manufacturer’s instructions.
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Statistical analysis
Data were expressed as mean ± standard deviation 
(SD) and were analyzed by one-way analysis of  variance 
(ANOVA). Results were considered statistically 
significant when P<0.05. All statistical analyses were 
calculated using Graph Pad Prism.
Results
Patient characteristics
All patients had been diagnosed and staged either as 
malignant SPNs (lung squamous cell carcinoma or 
adenocarcinoma) or benign SPNs by a histological 
evaluation of  surgical specimens (Supplementary Figure 
1).
There were no statistical differences regarding the 
baseline demographic variables among the three groups, 
so all the subjects were comparable. For malignant SPNs, 
there were 29 cases of  squamous carcinoma and 18 cases 
of  adenocarcinoma, which were all at an early stage of  
lung cancer (stage І). The benign SPNs were associated 
with various causes including infection, hamartoma, 
granuloma, and fibrosis. The detailed information of  
patients and healthy subjects was summarized in Table 
1. 
Supplementary Figure 1 
Supplementary Figure 1. Representative microscopic images of  human patients with SPNs. (A) Lung 
paraneoplastic tissue; (B) Benign solitary pulmonary nodule; (C) Lung adenocarcinoma; (D) Lung squamous cell 
carcinoma. Lung tissues were resected by surgery from patients and fixed in 10% formalin and embedded in 
paraffin wax. Then blocks were sectioned into 5 μm thickness and stained with hematoxylin and eosin (H&E) 
using a standard protocol. Scale bars: 100 μm. 
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Table 1. Characteristics of  patients with benign solitary pulmonary nodules (SPNs), patients with malignant SPNs, 
and healthy controls
Healthy controls Patients with benign SPNs
Patients with 
malignant SPNs
No. of  subjects 32 45 47
Gender Male Male Male
Age range (median) 39-69 (57) 38-72 (58) 40-79(62)
Active smokers (n) 21 37 39
Nodule size (average) 1.9 cm 2.4 cm







Squamous cell carcinoma 29
Cancer stage Ⅰ
Circulating levels of  sex hormones were decreased 
in patients with malignant SPNs
In this study, we measured both male and female sex 
hormones (testosterone, estradiol, and progesterone) 
in the serum of  all patients and health subjects. 
Testosterone is the predominant form of  androgen, 
whereas estradiol and progesterone are the principle 
forms of  estrogen. We found that testosterone 
(3.116±0.48 ng/ml), estradiol (23.55±2.34 pg/ml), and 
progesterone (0.261±0.048 ng/ml) in the serum of  
patients with malignant SPNs were all significantly lower 
than those in patients with benign SPNs (4.701±0.49 
ng/ml, 31.52±2.774 pg/ml, 0.451±0.052 ng/ml) and 
healthy subjects (5.581±0.372 ng/ml, 33.15±3.43 pg/
ml, 0.57±0.064 ng/ml) (all p<0.05, Figure 1). 
The levels of  three sex hormones tended to decline in 
Figure 1 
A B C 
Figure 1. Circulating sex hormones were decreased in male patients with malignant SPNs. Serum levels 
of  (A) testosterone (B) estradiol (C) progesterone were all significantly decreased in male patients with malignant 
SPNs, as compared with benign SPNs as well as normal controls. There was no significant difference in the levels 
of  three sex hormones between patients with benign SPNs and controls (P>0.05).
African Health sciences Vol 14 No. 2 June 2014359
patients with benign SPNs in contrast to healthy subjects, 
but the difference was not statistically significant 
(P>0.05). In addition, there was no difference found in 
Serum levels of  CEA were found to be abnormally 
elevated in only eight patients with lung adenocarcinoma, 
which were above the upper limit of  normal value 
(Supplementary Table 1). No abnormal elevation of  
CEA levels was observed in patients with lung squamous 
carcinoma and patients with benign SPNs. 
the levels of  sex hormones between adenocarcinoma and 
squamous carcinoma of  SPNs (P>0.05, Supplementary 
Figure 2), indicating that sex hormones levels are not 
related to lung cancer histological types.
Supplementary Table 1. Abnormal elevated serum levels of  CEA in 8 male patients with lung adenocarcinoma
Case Age (years) Smoking status Cancer stage CEA (ng/ml) Normal range (<5.0 ng/ml)
Case1 54 Current Ⅰ 25.4
Case1 48 Current Ⅰ 47.3
Case3 71 Former Ⅰ 35.8
Case4 67 Current Ⅰ 48.2
Case5 44 Current Ⅰ 8.2
Case6 49           Current     Ⅰ   18.6
Case7 58           Current Ⅰ 14.2
Case8 65           Current     Ⅰ   31.3
Supplementary Figure 2 
A B C 
Supplementary Figure 2. Serum levels of  sex hormones were similar in two types of  lung cancer. There 
was no significant difference in the levels of  (A) testosterone (B) estradiol (C) progesterone in patients with lung 
adenocarcinoma and patients with lung squamous carcinoma. 
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Circulating levels of  the inflammatory factors were 
increased in patients with SPNs 
It showed that the levels of  IL-1β (1.813±0.247 pg/
ml or 2.173±0.327 pg/ml), IL-6 (22.57±3.77 pg/ml 
or 27.37±3.686 pg/ml), and TNF-α (11.73±2.349 pg/
ml or 10.96±2.257 pg/ml) in the serum of  patients 
with benign SPNs or malignant SPNs were remarkably 
higher than those in healthy subjects (0.748±0.073 
pg/ml, 2.615±0.243 pg/ml, and 2.018±0.265 pg/ml)
(Figure 2). 
Figure 2 
A B C 
But there was no statistical difference in the levels 
of  the inflammatory cytokine between patients with 
malignant or benign SPNs (P>0.05). It thus suggested 
that measurement of  the inflammatory factors was 
unable to differentiate malignant from benign SPNs in 
patients.
Discussion
Serum measurement of  sex hormones is a valuable index 
in evaluating a variety of  organ dysfunctions, including 
reproductive and non-reproductive organ or tissues(13). 
Sex steroid hormones are primarily synthesized in the 
gonads, adrenal glands, and the feto-placental unit. Both 
male and female hormones are products of  oxidative 
metabolism of  cholesterol and their biosynthetic 
pathways are closely interrelated(15). Testosterone is 
the most important androgen and plays key roles in 
health and well-being in both males and females(16). 
Likewise, estradiol and progesterone are female 
hormones and essential for a variety of  physiological 
processes in both males and females(17). In addition 
to their centrality in sex development, sex hormones 
have significant effects on various organs or tissues 
other than reproductive system including skin, blood 
vessels, bone, muscle, coagulation, gastrointestinal tract, 
brain, lung, liver, kidney, and pancreas. Alterations of  
circulating sex hormones have been implicated in a wide 
range of  diseases(13). It is important to note that all sex 
steroid hormone receptors are found to be expressed 
in lung tissue(13), thus implying that sex hormones are 
closely associated with lung function and diseases. But 
the exact role of  sex hormones in the pathogenesis and 
progression of  lung cancer remains unclear, and there 
are actually some dramatic discrepancies in publishing 
reports. For example, certain studies suggested that 
androgens such as testosterone were decreased whereas 
estrogens such as estradiol were increased in patients 
with lung cancer(12,18). But in other studies, there 
were no such associations observed. Even the levels 
of  estradiol were reported to be decreased in patients 
with lung cancer(19). These confounding reports may 
be partly explained by gender differences in lung tumor 
patients caused by the variations in sex hormones levels 
in female patients. In addition, sex hormones levels may 
Figure 2. Serum levels of  the inflammatory factors were increased in patients with SPNs. (A) IL-1β (B) 
IL-6 (C) TNF-α levels were all increased in both patients with benign or malignant SPNs, as compared to controls. 
There was no significant difference in the levels of  the inflammatory factors between patients with benign SPNs 
and patients with malignant SPNs (P>0.05).
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vary in different cancer stages.  
  It is a clinical challenge to distinguish malignant from 
benign SPNs using the current imaging technologies. 
Given that sex hormones play important but distinctive 
roles in the etiology of  various lung diseases, we 
investigated the possibility of  sex hormones as a 
diagnostic marker for the screening of  lung cancer 
in patients with SPNs. Sex hormones levels differ in 
gender, especially in the case of  women of  childbearing 
age, pregnancy status and menopause. Furthermore, 
the levels of  sex hormones decrease with age(13). To 
rule out these potential confounders, we only collected 
male, age-matched patients with benign or malignant 
SPNs in this study. Moreover, malignant SPNs were 
confirmed to be an early stage of  lung cancer (stage I), 
thus excluding the possible interfering factor involving 
cancer stage. 
Our study showed that circulating sex hormones 
(testosterone, estradiol, and progesterone) were found 
to be decreased remarkably in patients with malignant 
SPNs. This seemed to be very unique and solely associated 
with lung cancer because the trend was not observed in 
patients with benign SPNs as compared to controls. To 
further explore whether the changes of  sex hormones 
related to lung cancer are distinctive, we also measured 
the levels of  CEA and the inflammatory cytokines in the 
serum of  all patients. It is aware that the increased levels 
of  CEA are related to caner stage and extent of  the 
lung, liver, breast, colon, and prostate(20). But it showed 
that only eight cases of  lung adenocarcinoma patients 
had abnormally elevated levels of  CEA, suggesting 
that this marker is not ideal for differentiation between 
malignant and benign SPNs. Similarly, the inflammatory 
cytokines were found to be elevated significantly in both 
patients compared to normal controls, but there was no 
statistical difference between patients with benign or 
malignant SPNs. Major causes of  benign SPNs include 
chronic smoking, granuloma, and infections, which 
could trigger inflammatory responses(4). So it is not a 
surprise that we observed high levels of  inflammatory 
cytokines in patients with benign SPNs. Likewise, 
patients with malignant SPNs had higher levels of  
inflammatory cytokines, suggesting that inflammation 
also occurred during the course of  lung tumorigenesis. 
It suggests that the inflammatory biomarkers are unable 
to distinguish lung cancer patients from benign SPNs 
patients. 
The mechanism that circulating sex hormones were 
reduced significantly in male patients with malignant 
SPNs is not clear. Indeed, sex hormones are involved 
in a wide-ranging and complex modulation of  cellular 
function in the lung. Under normal conditions, both 
androgen (testosterone) and estrogens (estradiol, 
progesterone) are proposed to have beneficial effects to 
modulate lung structure and function(13). For example, 
androgen enhances the inhibition of  immune response 
and stimulate the growth of  lung tissue(21), whereas 
estrogens participate in the regulation of  many pulmonary 
functions such as pulmonary vasodilation(17,19). We 
speculate that disorders of  lung function as a result of  
lung tumorigenesis may be the reason for the reduced 
sex hormones in patients. For benign SPNs, they may 
exert weak or little influence on sex hormones levels 
in the circulation. More rigorous studies are needed to 
clarify the underlying mechanisms.  
Conclusions
Based on our study, it showed that measurement of  
circulating sex hormones in the serum of  male patients 
with SPNs may have clinical potential to help distinguish 
malignant from benign SPNs. Considering that these 
patients with malignant SPNs were all at an early stage 
of  lung cancer, the changes of  sex hormones levels 
could be used as biomarkers for an early differentiation. 
In all, our finding is intriguing and worth further 
exploration. But it is a preliminary study and our 
speculative hypotheses require further investigation in 
larger population studies. 
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